In late 2014, the PARP inhibitor Olaparib was approved to treat ovarian cancer with BRCA mutations. Since then, research in the field of PARP has received extensive attention, especially in […]
B Cell Receptor (BCR) signaling pathway overview BCR is a transmembrane protein complex that controls B cell maturation, survival, apoptosis, and the production of plasma cell antibodies starting from the […]
Overview of cancer immunotherapy The most widely studied cancer immunotherapies are PD-1/PD-L1 immune checkpoint inhibitors and chimeric antigen receptor-T cell (CAR-T) therapy. With the expanded clinical applications, some defects of […]
Small nucleic acid-based drugs, namely oligonucleotide drugs, are short-chain nucleic acids consisting of dozens of nucleotides in series. At present, most oligonucleotide drugs are obtained through solid-phase chemical synthesis by […]
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus and possesses a positive-sense single-stranded RNA genome that contains 14 open reading frames (ORFs). Two […]
TIGIT is considered to be one of the most promising and potential targets, and a variety of evidence supports that TIGIT plays a key role in limiting the adaptive and […]
BOC Sciences provides varieties of fluorescent-labeled products and services to assist research in related fields.
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a […]
Drugs targeting HER2 have shown excellent clinical efficacy over the 20 years, achieving one milestone after another in the field of cancer therapeutics. This article mainly introduces the development history […]
Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]